PE20050133A1 - Piperazinas sustituidas heterociclicas - Google Patents

Piperazinas sustituidas heterociclicas

Info

Publication number
PE20050133A1
PE20050133A1 PE2003000974A PE2003000974A PE20050133A1 PE 20050133 A1 PE20050133 A1 PE 20050133A1 PE 2003000974 A PE2003000974 A PE 2003000974A PE 2003000974 A PE2003000974 A PE 2003000974A PE 20050133 A1 PE20050133 A1 PE 20050133A1
Authority
PE
Peru
Prior art keywords
bencisotiazol
ona
quinolin
piperazin
ethyl
Prior art date
Application number
PE2003000974A
Other languages
English (en)
Inventor
Jamie Marie Davis
Michael Anthony Walters
Tracy Fay Gregory
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20050133A1 publication Critical patent/PE20050133A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A COMPUESTOS DE FORMULA I DONDE Ar ES 1,2-BENCISOTIAZOILO, PIRIDILO, NAFTILO, ENTRE OTROS; A ES -(CH2)NCH2-; n ES 1-4; R2 Y R3 SON CADA UNO H, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; EL ANILLO Q ES UN HETEROCICLICO MONOCICLICO DE 5-7 MIEMBROS OPCIONALMENTE SUSTITUIDO. TAMBIEN REFERIDA A UN PROCESO PARA LA ELABORACION DE ESTOS COMPUESTOS CUYOS PREFERIDOS SON: 8-[2-(4-1,2-BENCISOTIAZOL-3-IL-PIPERAZIN-1-IL)-ETIL]-4,4-DIMETIL-3,4-DIHIDRO-1H-QUINOLIN-2-ONA; 8-[2-(4-1,2-BENCISOTIAZOL-3-IL-PIPERAZIN-1-IL)-ETIL]-6-FLUORO-4,4-DIMETIL-3,4-DIHIDRO-1H-QUINOLIN-2-ONA Y 8-[2-(4-1,2-BENCISOTIAZOL-3-IL-PIPERAZIN-1-IL)-ETIL]-4-ISOPROPIL-1H-QUINOLIN-2-ONA; ENTRE OTROS. DICHOS COMPUESTOS FORMAN COMPOSICIONES FARMACEUTICAS PARA TRATAR TRASTORNOS DEPRESIVOS, BIPOLARES, DE COMPORTAMIENTO DISRUPTIVO, ESQUIZOFRENICOS; ENTRE OTROS
PE2003000974A 2002-09-26 2003-09-23 Piperazinas sustituidas heterociclicas PE20050133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41383902P 2002-09-26 2002-09-26

Publications (1)

Publication Number Publication Date
PE20050133A1 true PE20050133A1 (es) 2005-03-22

Family

ID=32043299

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000974A PE20050133A1 (es) 2002-09-26 2003-09-23 Piperazinas sustituidas heterociclicas

Country Status (14)

Country Link
US (1) US20040067960A1 (es)
EP (1) EP1546145A1 (es)
JP (1) JP2006503846A (es)
AR (1) AR041376A1 (es)
AU (1) AU2003260882A1 (es)
BR (1) BR0314796A (es)
CA (1) CA2500115A1 (es)
GT (1) GT200300212A (es)
MX (1) MXPA05002003A (es)
PA (1) PA8583801A1 (es)
PE (1) PE20050133A1 (es)
TW (1) TW200413363A (es)
UY (1) UY27998A1 (es)
WO (1) WO2004029048A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272030A1 (en) * 2002-11-08 2004-06-07 Warner-Lambert Company Llc Phenylalkyl and pyridylalkyl piperazine derivatives
WO2005056540A1 (en) * 2003-12-08 2005-06-23 Warner-Lambert Company Llc Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
US20090076028A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched itraconazole
US20090076027A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
US20090082363A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched posaconazole
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
JP5714152B2 (ja) * 2014-03-26 2015-05-07 江蘇恒誼薬業有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
US10160778B2 (en) * 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN115521302B (zh) * 2022-09-20 2025-03-21 徐州医科大学 一种四氢（异）喹啉或吲哚啉类衍生物、组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6242450B1 (en) * 1998-07-27 2001-06-05 Eli Lilly And Company 5-HT1F antagonists
EP1188747B1 (en) * 1999-05-24 2005-09-07 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
HUP0301458A2 (hu) * 2000-10-26 2003-10-28 Smithkline Beecham Plc. Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása

Also Published As

Publication number Publication date
PA8583801A1 (es) 2004-05-07
JP2006503846A (ja) 2006-02-02
EP1546145A1 (en) 2005-06-29
AR041376A1 (es) 2005-05-11
WO2004029048A1 (en) 2004-04-08
MXPA05002003A (es) 2005-08-03
BR0314796A (pt) 2005-07-26
TW200413363A (en) 2004-08-01
AU2003260882A1 (en) 2004-04-19
CA2500115A1 (en) 2004-04-08
UY27998A1 (es) 2004-04-30
US20040067960A1 (en) 2004-04-08
GT200300212A (es) 2004-05-25

Similar Documents

Publication Publication Date Title
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
PE20021002A1 (es) Compuestos heterociclicos condensados
EA200600364A1 (ru) Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
PE20220425A1 (es) Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
PE20121148A1 (es) Compuestos heterociclicos y usos de los mismos
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
AR029614A1 (es) Derivados de 4-fenil-piridina, su uso, un proceso para prepararlos, y medicamentos que los contienen
PE20051039A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados
EA200300777A1 (ru) N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов для fsad
AR029717A1 (es) Derivados del pro-farmaco de 4-fenil-piridina
EA200300792A1 (ru) Хиназолины в качестве ингибиторов ммр-13
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
EA200601235A1 (ru) Производные тиазола
ES2187983T3 (es) Derivados 1,2,3,4-tetrahidronaftaleno sustituidos.
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20081496A1 (es) Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1
PE20080136A1 (es) Arilsulfonamidas sustituidas como agentes antivirales
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE75199A1 (es) Derivado de quinolina util como antagonista de neuroquinina
ATE493404T1 (de) Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren
AR034585A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal